At the closing ceremony of NC-BIIS 2026, Duke Distinguished Professor and CAS Foreign Member Dr. Xiaofan Wang delivered a forward-looking address on how China's pharmaceutical industry has reached an "inflection point" after 30 years of transformation from imitation to genuine innovation. Dr. Wang highlighted key growth directions including cell and gene therapy, antibody-drug conjugates (ADCs), and AI-driven drug discovery. He emphasized that the US remains the global leader in biomedical innovation and that US-China cooperation — not decoupling — is essential for addressing humanity's biggest health challenges. The address underscored the unique role of organizations like SAPA in bridging the two ecosystems.